价格

Sanofi-Aventis Deutschland Gmbh

ACTIVE

Utländsk Adr - Foreign Addr, 瑞典www.sanofi-aventis.deSubsidiary10,001+ 名员工成立于: 1863-01-01

别名:

tor süd h 600, tor 47

r&d biologics research protein therapeutics

隶属于赛诺菲安万特

概览

试验阶段分布

阶段

试验数

占比

不适用

28.6%

1 期

21.4%

试验状态分布

进行中（未招募）

71.4%

已完成

28.6%

相关临床试验

该机构主办的试验（14）

Randomized controlled trial to evaluate the digital health application My Dose Coach

Efficacy and safety of using insulin glargine 300 U/mL in patients with type 2 diabetes on basal insulin and oral antidiabetic drugs failing to achieve their blood sugar targets

Efficacy and safety of using insulin glargine in patients with type 2 diabetes on non-insulin antidiabetic therapy failing to achieve control of blood sugar: the Toujeo-1 trial

Efficacy and safety of using insulin glargine 300 U/mL in patients on advanced insulin therapy with type 1 or type 2 diabetes failing to achieve their glycemic targets. The Toujeo-Neo trial.

Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents. A multicenter, prospective, crossover, open randomized clinical phase-IV trial. - HAPPY

进行中（未招募）

Apr 2009332 名受试者

Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis - TRICAPEKA

进行中（未招募）

Apr 200612 名受试者

Efficacy and safety of intra-articular multiple doses of 500 mg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis*After the clinical start of the study, an extension of the follow-up period has been established by Amendment n° 2, extending the observation period by further 26 weeks; thus, the overall study duration will become totally 39 weeks. - TRICAP

1 期

进行中（未招募）

Feb 2006550 名受试者

Efficacy and safety of intra-articular multiple doses of 500 mg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis*After the clinical start of the study, an extension of the follow-up period has been established by Amendment n° 2, extending the observation period by further 26 weeks; thus, the overall study duration will become totally 39 weeks. - Not applicable

进行中（未招募）

Feb 2006550 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

PHILIPPINES

Philippines FDA

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

APIDRA 100 UNIDADES/ML,SOLOSTAR SOLUCION INYECTABLE EN PLUMA PRECARGADA

CIMA_AEMPS

2026-08-17

Zaltrap 25mg/ml Concentrate for Solution for Infusion

NPRA

2025-11-28

APIDRA SOLOSTAR 100 UNITS/ML, SOLUTION FOR INJECTION IN A PRE-FILLED PEN

NPRA

2025-11-28

Toujeo 300 units/ml Solution for Injection in Pre-Filled Pen

NPRA

2025-11-28

Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen

NPRA

2025-11-28

Eloxatin 5mg/ml, concentrate for solution for infusion

NPRA

2025-11-28

JEVTANA 60mg CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

NPRA

2025-11-28

Soliqua SoloStar 100units/mL+50mcg/mL solution for injection in a pre-filled pen

NPRA

2025-11-28

LANTUS SOLOSTAR 100IU/ML SOLUTION FOR INJECTION IN A PRE-FILLED PEN

资讯

暂无资讯文章

返回机构列表